drugs / English

add

Veteran safety Tashaun Gipson has been suspended by the NFL for the first six games of the 2024 season for…

(MedPage Today) -- The FDA approved donanemab (Kisunla) for the treatment of adults with early symptomatic Alzheimer's disease with confirmed amyloid pathology, the agency announced Tuesday. This includes Alzheimer's patients with mild…

The Food and Drug Administration approved Eli Lilly’s Kisunla for mild or early cases of dementia caused by Alzheimer’s.

“Paul looked like he used a key to scoop some substance out of a bag which he lifted to his nose and sniffed," an eyewitness alleged to the Sun.

The FDA has approved a new medication for people with Alzheimer’s disease. Eli Lilly’s Kisunla (donanemab) is a once-monthly injection intended for adults with early symptomatic Alzheimer's disease.

The upcoming docuseries Ibiza Narcos, which starts on Sky Documentaries later this week, tells how the island turned into a mecca for drug-fuelled partying and gang warfare

Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease

A study has demystified the genetic underpinnings of schaftoside, a vital compound in traditional Chinese medicine (TCM) with potential as a COVID-19 therapeutic.

A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday.

Donanemab (Kisunla), a new drug to treat Alzheimer's disease, was approved by the U.S. Food and Drug Administration on Tuesday.

The companies are charging “unconscionably high prices” that are above those paid in other countries, Biden said in an editorial with Vermont Sen. Bernie Sanders.

A Manchester University graduate has been jailed after being found guilty of importing and selling illegal medicines including Viagra Antoine Christopher Kolias aged 31 , was sentenced on Friday 28 June to a total of three and a half…

The new drug Kisunla promises to slow the disease in patients, but they will have to balance safety risks and reimbursement issues.

The U.S. Food and Drug Administration on Tuesday approved Eli Lilly’s treatment for early Alzheimer’s, making it the second therapy for slowing the progression of the brain-wasting disease that will be available to U.S. patients.

A new study from researchers at the University of California San Diego shows that interest in microdosing spiked 1,250% between 2015 and 2023.

275936 at https://natlawreview.com/article/healthcare-execs-face-federal-drug-charges-landmark-telehealth-case

Americans on Medicaid moved closer to receiving coverage for weight loss treatments nearly a year after an Ohio congressman introduced legislation to expand access.

The Food and Drug Administration granted approval to Eli Lilly's Alzheimer's drug, which was found to slow progression of the disease by about a third, the company announced Tuesday.

The Food and Drug Administration (FDA) on Tuesday approved Eli Lilly’s Alzheimer’s drug, the company announced, clearing the way for another entry into the market of a new class of drugs that moderately slows the disease’s progression. The…